Get the Stockscreener App
10.38
20.00%
1.73
After Hours:
10.22
-0.16
-1.54%
Regenxbio Inc stock is traded at $10.38, with a volume of 1.93M.
It is up +20.00% in the last 24 hours and up +0.68% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$8.65
Open:
$9.75
24h Volume:
1.93M
Relative Volume:
2.13
Market Cap:
$525.47M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.9734
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
+12.34%
1M Performance:
+0.68%
6M Performance:
+4.95%
1Y Performance:
+63.72%
1-Day Range:
$9.725
$10.76
1-Week Range:
$8.01
$10.76
52-Week Range:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
10.38 | 437.89M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
RGNX'S "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements - Investing.com India
H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
REGENXBIO commends women leadership driving mission on International Womens Day - Traders Union
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - bdtonline.com
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why REGENXBIO Inc. stock remains a top recommendation2026 Chart Watch & AI Based Trade Execution Alerts - Naître et grandir
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty - TipRanks
REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - bdtonline.com
REGENXBIO Inc. Sued for Securities Law Violations – - GlobeNewswire
Team powers gene therapy mission, REGENXBIO asserts - Traders Union
The Analyst Verdict: Regenxbio In The Eyes Of 8 Experts - Benzinga
Assessing Where Regenxbio Stands After FY25 Results (NASDAQ:RGNX) - Seeking Alpha
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Regenxbio: Q4 Earnings Snapshot - theheraldreview.com
Morgan Stanley Lowers Price Target for RGNX but Maintains Overwe - GuruFocus
REGENXBIO Q4 Earnings Call Highlights - MarketBeat
REGENXBIO outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases - MSN
RegenXBio Earnings Call Balances Gene Therapy Risks - TipRanks
REGENXBIO (RGNX) Eyes Key Developments in 2026 Amid Robust Pipel - GuruFocus
Regenxbio stock: Clear Street reiterates Buy on gene therapy data By Investing.com - Investing.com Canada
Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com
REGENXBIO (NASDAQ:RGNX) Posts Earnings Results - MarketBeat
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
Aug Catalysts: Is REGENXBIO Inc impacted by rising ratesQuarterly Profit Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Morgan Stanley cuts Regenxbio stock price target on model updates - Investing.com Nigeria
Morgan Stanley cuts Regenxbio stock price target on model updates By Investing.com - Investing.com Australia
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com UK
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - marketscreener.com
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com UK
Earnings call transcript: Regenxbio misses Q4 2025 expectations, stock dips - Investing.com
REGENXBIO Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Regenxbio: Fourth Quarter Financial Overview - Bitget
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
REGENXBIO ($RGNX) Releases Q4 2025 Earnings - Quiver Quantitative
Regenxbio Q4 revenue rises but loss widens as costs increase - TradingView
Regenxbio Earnings Report: Q4 Overview - Benzinga
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Yahoo Finance
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):